Calydon Overview
- Status
- Acquired/Merged
- Latest Deal Type
- M&A
- Latest Deal Amount
- $17.7M
Calydon General Information
Description
Developer of therapeutic products for cancer. The company is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies.
Contact Information
Primary Industry
Biotechnology
Acquirer
Primary Office
- 1331 Hillview Drive
- Menlo Park, CA 94025
- United States
Calydon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 05-Sep-2001 | $17.7M | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
| 2. Early Stage VC | 11-Dec-1997 | 000.00 | 000.00 | Completed | Product Development | |
| 1. Early Stage VC | $3.8M | $3.8M | Completed |
Calydon Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| AmBex Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Genesis Merchant Partners | Lender/Debt Provider | Minority | 000 0000 | 000000 0 | |
| Kevin D'Silva | Angel (individual) | Minority | 000 0000 | 000000 0 | |
| Perseus (Bethesda) | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Sequoia Capital | Venture Capital | Minority | 000 0000 | 000000 0 |